人血清白蛋白融合技术研究进展

人血清白蛋白是血液中含量最丰富的蛋白,它半衰期长,且具有运输药物的功能,这使其成为理想的药物栽体.作为延长药物半衰期的新技术,白蛋白融合技术是近年来发展迅速、应用广泛的蛋白质工程技术.通过共价偶联、非共价偶联、纳米包裹和融合蛋白的方式可实现白蛋白与药物分子的偶联,使药物分子的药代动力学得到明显改善.系统介绍了白蛋白融合技术的主要方式、进展以及发展方向.随着白蛋白和相关受体蛋白作用机制的研究不断深入,基于结构的白蛋白融合技术将进一步提高白蛋白融合技术在长效药物开发中的应用.

Advance of Human Serum Albumin Fusion Technology

Human serum albumin （ HSA）, the most abundant protein in human blood, has an extremely long half - life time, and functions as a drug binder, making it be an ideal cartier of drugs. As a new technology of enhancing the half - life time of pharmaceuti- cals, HSA - based fusion technology has been rapidly developed and widely used in current drug engineering. The half - life of drugs can be extended effectively through conjugations with HSA through covalent, non - covalent binding, micro - capsuled, and protein fu- sion. We reviewed the methods of HSA - based fusion technology. Further investigation of interaction of HSA with its receptors could facilitate the development of this technology, and structure - based HSA fusion technology will further promote the application of HSA fusion technology in developing long - acting pharmaceuticals.